The original success of the copyright undeniably reshaped the medication landscape, but investing in companies primarily reliant on generic versions presents a challenging picture. Although early profits were significant, the expiration of patents and the emergence of discounted alternatives have diminished sales. Consequently, a thorough evaluatio